Submissions from 2018
Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study., Leigh G Seamon, James J Java, Bradley J Monk, Richard T Penson, Jubilee Brown, Robert S Mannel, Anna Oaknin, Mario M Leitao, Eric L Eisenhauer, Harry J Long, Shu Y Liao, and Krishnansu S Tewari
Refractory Schizophrenia, Attempted Suicide, and Withdrawal of Life Support: A Clinical Ethics Case Report., Cory Taylor, Jamie C Fertal, and Solomon Liao
Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study., William P Tew, Michael W Sill, Joan L Walker, Angeles Alvarez Secord, Albert J Bonebrake, Jeanne M Schilder, Ashley Stuckey, Laurel Rice, Krishnansu S Tewari, and Carol A Aghajanian
The Hospital Antimicrobial Use Process: From Beginning to End., William R Truong and Jason Yamaki
Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancer., Juliet E Wolford and Krishnansu S Tewari
